Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

January 31, 2011

Conditions
Advanced Solid Tumors
Interventions
DRUG

cediranib (RECENTIN TM, AZD2171)

20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)

Trial Locations (5)

Unknown

Research Site, Hamilton

Research Site, Toronto

Research Site, Vancouver

Research Site, Copenhagen

Research Site, Herlev

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY